Just out from the NeuroCyto team: the ultrastructure of actin rings revealed
Our work on the ultrastructure of the periodic actin/spectrin scaffold along axons is out in Nature Communications.
Indéfini
L'Institut de NeuroPhysiopathologie (INP) est un centre d'excellence pour la formation et la recherche qui allie la recherche fondamentale et translationnelle pour étudier l'organisation, la fonction et l'interaction des cellules neurales, les bases moléculaires et cellulaires des principales maladies du cerveau, et développer des stratégies de thérapies cellulaires et moléculaires innovantes.
Equipes de recherche
Plateforme NeuroTimone (PFNT)
La PFNT (Plateforme NeuroTimone) est un ensemble cohérent d'outils d'exploration en neurobiologie permettant des investigations aux échelles moléculaires, cellulaires et intégrées.
A la Une
-
Vect-Horus and RadioMedix announce signing of a Letter of Intent to co-develop a radio-theranostic agent for GlioblastomaThis partnership will marry the expertise of Vect-Horus in targeting tumors with its technology VECTrans® and the know-how of RadioMedix in developing and conducting pre-clinical evaluation and clinical trials with radiopharmaceuticals.
For more information, please follow this link or download the pdf version.
-
Michel Khrestchatisky gives a talk at the « Nanomedicine for treating cancer and brain diseases » symposiumIn the context of the Euronanomed projects for Action on Nanomedicine under Horizon 2020, a Symposium will be held at the Luminy campus in Marseille on March 8, 2019. Dr. Khrestchatisky will give a talk titled "Molecular vectors for drug delivery into the brain and tumors".
For more information, please visit the symposium website or download the pdf version of the program.
-
Yvon Berland mentions Vect-Horus as one of the three 3 AMU biotech success storiesIn an interview published by "La Provence" on November 30, 2018 Yvon Bertrand, President of Aix-Marseille University, explains that AMU is very proud of its contribution to the field of Artificial Intelligence but also to the development of companies such as "First Light Imaging", VECT-HORUS or Innate-Pharma. They are real success stories from public research.
-
L'équipe 9 a participé à une revue collective sur les structures moléculaires de tauL'équipe 9 "Cytosquelette et Neurophysiopathologie" de l'INP, conjointement avec plusieurs groupes leaders dans l'étude de la biologie de tau, a participé à une revue collective qui vient de sortir dans Acta Neuropathologica Communications. Cette revue résume les récentes avancées moléculaires , en physiologie comme en pathologie, de cette protéine à la structure si difficile à appréhender..
A lire (open access) : https://link.springer.com/article/10.1186/s40478-019-0682-x
Titre : The elusive tau molecular structures: can we translate the recent breakthroughs into new targets for intervention?
-
Nouvel article de l'équipe cytosquelette et neurophysiopathologieLe dernier travail de l'équipe 9 de l'INP : "Tau regulates the microtubule-dependent migration of glioblastoma cells via the Rho-ROCK signaling pathway" est maintenant publié dans J. cell. Science. Ces travaux identifient pour la première fois le rôle et les mécanismes impliquant la proteine tau dans les processus d'invasion des glioblastomes, tumeurs cérébrales très agressives. Ces travaux soulignent le rôle de la protéine Tau comme une cible commune entre les cancers et la neurodégénératio
-
Hervé Kovacic élu président du CNU section 85Professeur de Biophysique et Biomathématique à la Faculté de Pharmacie de Marseille, Hervé Kovacic est élu pour un mandat de six ans. La section CNU 85 gère les qualifications, promotions et primes des enseignant-chercheurs spécialisés en sciences physico-chimiques et ingénierie appliquée à la santé. Docteur Pascale Barbier, elle aussi membre de l'équipe 9 de l'INP a été nominé par le Ministère dans la même section CNU.
-
Jean-Michel Paumier successfully defended his doctoral thesisJean-Michel Paumier, former PhD student in Team 1 (Neural Plasticity and Degeneration), has successfuly defended his thesis on Wednesday the 05th of December 2018. After few hours of a nice presentation followed by many questions, the examining board congratulated Jean-Michel for his good work and granted him the diploma of doctor in Neuroscience.
-
Vect-Horus announces agreement with Johnson & Johnson innovationVect-Horus announced today the signing of a research collaboration agreement with Janssen Pharmaceuticals, Inc. one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The goal of this collaboration is to use Vect-Horus’ proprietary technology to transport various Janssen monoclonal antibodies to the brain for the treatment of neurodegenerative diseases. This deal was facilitated by Johnson & Johnson Innovation Limited.
Pages
L'INP en chiffres
- 126 membres
- 44 chercheurs
- 48 chercheurs assistants
- 12 post-doctorants
- 11 doctorants
INP & Vect-Horus first day off in Black Stone pub
On thursday december the 12th, most of INP and Vect-Horus members got together and spent a day in the Black Stone pub, Marseille, to celebrate the fact that nearly two years after its creation, the Institute of NeuroPhysiopathology is finally located on Tmone Campus.
Indéfini
Michel KHRESTCHATISKY invited to the third edition of “Translational neuroscience Day: challenges and opportunities” co-organized by DHUNE and NeurATRIS
Michel KHRESTCHATISKY, Director of the UMR7051 Institute of Neurophysiopathology at Aix-Marseille University / CNRS and co-founder of VECT-HORUS was invited at the third edition of “Translational neuroscience Day: challenges and opportunities” co-organized by DHUNE and NeurATRIS and hosted by BioFIT on December 10, 2019 (https://www.biofit-event.com/translational-neuroscience).
Indéfini
Maeva MONTALEYTANG and Noé DUMAS from the GlioME team presented their research on nanoparticles at the SFNano C'Nano congress
Maeva and Noé presented their poster at the SFNano C'Nano conference entitled "Preclinical evaluation of a paclitaxel nanoprodrug for glioblastoma therapy".
Indéfini
Un nouvel arrivant dans l'équipe 5
L'équipe 5 a le plaisir d'accueillir en stage du 1er décembre 2019 au 31 mars 2020, Théo Loignon étudiant à l'école d'ingénieur de Bordeaux ei.cesi. Théo travaillera avec Jean-Philippe Dales sur l'imagerie chimique du tissu nerveux au cours de la neuroinflammation.
Indéfini
New publication for the Neuro-inflammation and Multiple Sclerosis team (INP team 5) in Cytokine about the immunomonitoring of infliximab biotherapies
In this paper, Daniel Bertin evaluated the immunological follow-up of patients suffering from chronic inflammatory diseases and receiving anti-TNF biotherapy. Three commercial ELISA assays for monitoring soluble through levels of infliximab and anti-infliximab antibodies in serum showed a good global correlation of results. However, some quantitative discrepancies could change clinical decision. As a consequence, Daniel Bertin recommended to keep the same kit to perform a longitudinal follow-up of patients.
Indéfini
Aurélie Tchoghandjian-Auphan, CRCN CNRS from the GlioME team, was recently granted by ARC fondation for her project "Effects of Smac mimetics treatment on glioblastomas immune response" .
Aurélie Tchoghandjian-Auphan, CRCN CNRS from the GlioME team, in the Insitute of NeuroPhysiopathology, UMR CNRS 7051, was recently granted by ARC fondation for her project "Effects of Smac mimetics treatment on glioblastomas immune response".
Subsequently she was interviewed by :
- France 3 (JT 19/20 PACA diffusion du 15/11: 7'09 à 9'45) ;
- Provence Azur (18/11/2019) ;
- 20 Minutes Marseille (18/11/2019)
- La Provence
Indéfini
DESU « Exploration et traitement des maladies auto-immunes »
Vous êtes médecin, pharmacien, interne en médecine ou biologie médicale et intéressé par les maladies auto-immunes et inflammatoires chroniques ?
Indéfini
GlioME team in collaboration with INT (Institute of Neurosciences Timone) published a new study in Journal of Neuroinflammation on the effect of Bevacizumab on glioblastoma-bearing mice, using 2-photon imaging
Our data show that VEGF blockade leads to an increased recruitment of monocytes and to an adjustment of dendritic cell subsets’ profiles, differing in their ability to induce an adaptive immune response. Altogether, they provide important new insights into the effects of Bevacizumab at the cellular level and into the spatio-temporal evolution of intra-tumoral innate immune cell densities.
Indéfini
Le Pr Hervé Kovacic rejoint le comité de rédaction de « Antioxidant Redox Signaling »
Le principal journal à comité de lecture consacré à la compréhension de l'impact vital des processus d'oxygénation et d'oxydo-réduction (redox) sur la santé et les maladies humaines, en explorant les principaux enjeux des thérapies génétiques, pharmaceutiques et nutritionnelles à base de redox.
Pour plus d'informations visitez le site internet d'ARS.
Français
Partenaires
Aix Marseille Université | All rights reserved - Legal notice